Genmab — Juni 2015
-
Det er ren luksus
så kan de sige hvad de vil i valgkampen -
-
-
-
bid mærke i data cutoff januar 2016 - så det er ikke opdateret data, responserne kan være blevet dybere
-
nej solsen det er fra det gamle gen I/II studie
-
det er stadig 29%
-
Men vildt 31 % af patienterne havde både fået Revlimid, Velcade, Kyprolis og Pomalyst inden !
-
men over 38% af patienterne havde over 50% sænkning i paraprotein og 16% havde over 90% sænkning.
-
Så vidt jeg kan se af chartet havde over 14 patienter (dvs. 13% af alle i studiet) 100% sænkning af paraprotein. Så der er mulighed for flere CR med tiden
-
Initial responses deepened with
continued DARA treatment in
many patients
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind